Identification
- Composition (DCI)
- darolutamide
- Manufacturer
- BAYER S.A
- ATC code
- L02BB06
- Presentation
- Boite de 112
- Schedule / Reimb.
- A
- Hospital price
- 26292.00 MAD
Indications
NUBEQA est indiqué chez l’homme adulte dans le traitement du - cancer de la prostate résistant à la castration non métastatique (CPRCnm) pour les patients ayant un risque élevé de développer une maladie métastatique; - cancer de la prostate hormonosensible métastatique (CPHSm) en association avec le docétaxel et un traitement par suppression androgénique.
Find an open pharmacy
On-call pharmacies near you
About NUBEQA 300 MG
NUBEQA 300 MG is marketed in Morocco by BAYER S.A and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of NUBEQA 300 MG, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about NUBEQA 300 MG
Answers to common questions from Moroccan patients about this drug.